Genomic profiling of inflammatory breast cancer: a review.

[1]  F. Bertucci,et al.  Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  K. Baggerly,et al.  Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers , 2013, Breast Cancer Research.

[3]  Rosette Lidereau,et al.  miRNA expression profiling of inflammatory breast cancer identifies a 5‐miRNA signature predictive of breast tumor aggressiveness , 2013, International journal of cancer.

[4]  Yu Cao,et al.  Inflammatory breast cancer (IBC): clues for targeted therapies , 2013, Breast Cancer Research and Treatment.

[5]  T. Ideker,et al.  Genome wide proteomics of ERBB2 and EGFR and other oncogenic pathways in inflammatory breast cancer. , 2013, Journal of proteome research.

[6]  P. Vermeulen,et al.  Modeling and characterization of inflammatory breast cancer emboli grown in vitro , 2013, International journal of cancer.

[7]  F. Bertucci,et al.  Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets , 2013, Clinical Cancer Research.

[8]  S. Krishnamurthy,et al.  Genomic Profiling of Pre-Clinical Models of Inflammatory Breast Cancer Identifies a Signature of Epithelial Plasticity and Suppression of TGFò Signaling , 2012 .

[9]  T. Delozier,et al.  Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. , 2012, The Lancet. Oncology.

[10]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[11]  K. Aird,et al.  Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration , 2011, British Journal of Cancer.

[12]  S. Merajver,et al.  International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Daniel Birnbaum,et al.  High-Resolution Comparative Genomic Hybridization of Inflammatory Breast Cancer and Identification of Candidate Genes , 2011, PloS one.

[14]  Y. Ye,et al.  The lymphovascular embolus of inflammatory breast cancer exhibits a Notch 3 addiction , 2011, Oncogene.

[15]  Patrick Pauwels,et al.  Array-Based DNA Methylation Profiling for Breast Cancer Subtype Discrimination , 2010, PloS one.

[16]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[17]  I. Van der Auwera,et al.  Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype , 2010, British Journal of Cancer.

[18]  M. Desilvio,et al.  Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  F. Bertucci,et al.  Gene expression profiling of inflammatory breast cancer , 2010, Cancer.

[20]  E. Sahai,et al.  Intravital imaging illuminates transforming growth factor beta signaling switches during metastasis. , 2010, Cancer research.

[21]  Joshua F. McMichael,et al.  Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft , 2010, Nature.

[22]  Carsten Denkert,et al.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Annuska M. Glas,et al.  The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer , 2010, Breast Cancer Research and Treatment.

[24]  W. Grizzle,et al.  Dual effects of TGF-β on ERα-mediated estrogenic transcriptional activity in breast cancer , 2009, Molecular Cancer.

[25]  Erik Sahai,et al.  Localised and reversible TGFβ signalling switches breast cancer cells from cohesive to single cell motility , 2009, Nature Cell Biology.

[26]  P. Levine,et al.  Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer , 2009, Nature Cell Biology.

[27]  David Cameron,et al.  A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer , 2009, Nature Medicine.

[28]  John N Weinstein,et al.  A stromal gene signature associated with inflammatory breast cancer , 2008, International journal of cancer.

[29]  F. Bertucci,et al.  Defining the molecular biology of inflammatory breast cancer. , 2008, Seminars in oncology.

[30]  Selin Carkaci,et al.  Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings , 2008, Breast Cancer Research and Treatment.

[31]  Rosette Lidereau,et al.  BMC Cancer BioMed Central Research article NF-kappa B genes have a major role in Inflammatory Breast Cancer , 2008 .

[32]  E. van Marck,et al.  Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis , 2007, British Journal of Cancer.

[33]  J. Ross,et al.  Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  S. Hilsenbeck,et al.  Molecular Heterogeneity of Inflammatory Breast Cancer: A Hyperproliferative Phenotype , 2006, Clinical Cancer Research.

[35]  E. van Marck,et al.  Nuclear Factor-κB Signature of Inflammatory Breast Cancer by cDNA Microarray Validated by Quantitative Real-time Reverse Transcription-PCR, Immunohistochemistry, and Nuclear Factor-κB DNA-Binding , 2006, Clinical Cancer Research.

[36]  Andrea Bild,et al.  Gene Expression Profiles of Multiple Breast Cancer Phenotypes and Response to Neoadjuvant Chemotherapy , 2006, Clinical Cancer Research.

[37]  M. Cassone,et al.  Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis , 2005 .

[38]  Daniel Birnbaum,et al.  Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. , 2005, Cancer research.

[39]  Roman Rouzier,et al.  Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  F. Bertucci,et al.  Gene Expression Profiling for Molecular Characterization of Inflammatory Breast Cancer and Prediction of Response to Chemotherapy , 2004, Cancer Research.

[41]  Rosette Lidereau,et al.  Molecular Profiling of Inflammatory Breast Cancer , 2004, Clinical Cancer Research.

[42]  F. Bertucci,et al.  Immunophenotypic analysis of inflammatory breast cancers: identification of an ‘inflammatory signature’ , 2004, The Journal of pathology.

[43]  Josef Gotzmann,et al.  Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. , 2004, Mutation research.

[44]  M. Espié,et al.  Two prognostic groups of inflammatory breast cancer have distinct genotypes. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  E. van Marck,et al.  Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression , 2003, British Journal of Cancer.

[46]  M. Espié,et al.  Evidence of chromosome regions and gene involvement in inflammatory breast cancer , 2002, International journal of cancer.

[47]  S. Merajver,et al.  Persistent E-Cadherin Expression in Inflammatory Breast Cancer , 2001, Modern Pathology.

[48]  L. Zelek,et al.  Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: Prevalence of alterations in inflammatory breast cancers , 2000, Oncogene.

[49]  S. Merajver,et al.  A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  G. Hortobagyi,et al.  Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center , 1997, Cancer Chemotherapy and Pharmacology.

[51]  Z. Baloch,et al.  Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. , 1995, Journal of the American College of Surgeons.

[52]  B. Asselain,et al.  Inflammatory breast cancer. Determination of prognostic factors by univariate and multivariate analysis , 1987, Cancer.